Stock comparison
JOHNSON & JOHNSON is 329.3x more valuable than UroGen Pharma Ltd. by market capitalization ($618.61 B vs $1.88 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 329.3x more valuable than UroGen Pharma Ltd. by market capitalization ($618.61 B vs $1.88 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 329.3x more valuable than UroGen Pharma Ltd. by market capitalization ($618.61 B vs $1.88 B).
Revenue leader
JNJ
URGN: $109.79M vs JNJ: $94.19B.
Profit leader
JNJ
URGN: -$153.49M vs JNJ: $26.80B.
Margin leader
JNJ
URGN: -139.8% vs JNJ: 28.5% net margin.
| Metric | URGN | JNJ |
|---|---|---|
| Market cap | $1.88 B | $618.61 B |
| US-listed rank | #2193 | #18 |
| Revenue (latest FY) | $109.79M | $94.19B |
| Net income (latest FY) | -$153.49M | $26.80B |
| Net margin | -139.8% | 28.5% |
| P/E (trailing FY) | - | 23.1x |
| SEC filings | 548 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 329.3x more valuable than UroGen Pharma Ltd. by market capitalization ($618.61 B vs $1.88 B).
In their latest fiscal years, UroGen Pharma Ltd. reported $109.79M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: UroGen Pharma Ltd. and JOHNSON & JOHNSON, or browse the full rankings.